Value analysis of the MOG-AR score and inflammatory indexes in predicting the recurrence risk in patients with myelin oligodendrocyte glycoprotein antibody-associated disease
10.3760/cma.j.cn115455-20250123-00093
- VernacularTitle:MOG-AR评分和炎性指标预测髓鞘少突胶质细胞糖蛋白抗体相关疾病复发风险的价值分析
- Author:
Yongfang TIAN
1
;
Jiayong WU
Author Information
1. 徐州市中心医院神经内科，徐州 221000
- Publication Type:Journal Article
- Keywords:
Myelin-oligodendrocyte glycoprotein;
Recurrence;
Forecasting;
MOG-AR score;
Platelet-to-lymphocyte ratio
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(9):843-849
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the value of MOG-AR score and inflammatory indexes in predicting the recurrence risk in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).Methods:The clinical data of 33 patients with MOGAD from June 2020 to January 2024 in Drum Tower Hospital Affiliated to Nanjing University Medicine School were retrospectively analyzed. For the MOGAD patients, the gender, age at onset ≥ 45 years, attack phenotype, status of immunotherapy and oral glucocorticoid time were recorded, and the MOG-AR score was calculated. All patients were followed up for 1 year, the status of recurrence was recorded, and the patients were divided into non-recurrence group and recurrence group. Additionally, 20 healthy subjects who underwent physical examination were selected as the healthy control group. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) were calculated in the three groups, and the systemic immune-inflammation index (SII) and systemic inflammatory response index (SIRI) were evaluated.Results:Among the 33 patients with MOGAD, 19 patients had no recurrence within 1 year, and 14 patients had recurrence within 1 year, with a recurrence rate of 42.4%. The proportion of oral glucocorticoid time < 3 months and MOG-AR score in recurrence group were significantly higher than those in non-recurrence group: 6/14 vs. 0 and (9.93 ± 1.98) scores vs. (7.37 ± 2.24) scores, and there were statistical differences ( P<0.01); there were no statistical difference in gender composition, age at onset ≥45 years, attack phenotype and proportion of non-immunotherapy between the two groups ( P>0.05). The PLR and SIRI in recurrence group were significantly higher than those in healthy control group: 163.64 (100.42, 237.67) vs. 100.26 (88.57, 114.22) and 1.49 (0.82, 3.52) vs. 0.57 (0.47, 0.86), the NLR and SII in recurrence group and non-recurrence group were significantly higher than those in healthy control group: 3.64 (1.91, 7.53) and 2.85 (1.78, 4.67) vs. 1.62 (1.23, 2.18), 786.82 (533.90, 1 968.28) and 525.00 (370.89, 1 013.88) vs. 283.86 (263.43, 455.51), and there were statistical differences ( P<0.05); there were no statistical difference in PLR and SIRI between non-recurrence group and healthy control group ( P>0.05), there were no statistical difference in PLR, NLR, SII and SIRI between recurrence group and non-recurrence group ( P>0.05); there was no statistical difference in MLR among three groups ( P>0.05). Conclusions:The MOG-AR score can effectively predict the risk of MOGAD recurrence, providing a simple tool for the early identification of high-risk patients. It is recommended that the continuous oral glucocorticoid time should be ≥ 3 months to reduce the risk of recurrence. In addition, the significant elevation of PLR and SIRI may serve as potential indexes for predicting the recurrence of MOGAD.
